Who Owns ORIC Pharmaceuticals Company?

Who Owns ORIC Pharmaceuticals?

Understanding ORIC Pharmaceuticals' ownership is key to grasping its strategic direction and accountability. The company transitioned to public ownership via its IPO in April 2020.

Founded in 2014 and headquartered in South San Francisco, California, ORIC Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on overcoming cancer resistance.

As of July 23, 2025, ORIC Pharmaceuticals has a market capitalization of $1.01 billion with 85.2 million shares outstanding.

The ownership landscape of ORIC Pharmaceuticals is dynamic, reflecting its journey from a private startup to a publicly traded entity. Initially, founders and early investors held significant stakes. Following the IPO, ownership broadened to include institutional investors, mutual funds, and individual retail investors. Key institutional holders often exert considerable influence through their substantial shareholdings and board representation. The company's focus on developing novel therapies, such as its work on ORIC Pharmaceuticals BCG Matrix, attracts investment from entities specializing in the biotechnology sector.

ORIC Pharmaceuticals was founded in 2014 by a distinguished group of scientists: Charles L. Sawyers, Scott Lowe, and Richard A. Heyman. Richard A. Heyman, who later assumed the role of Chairman of the board, brought significant prior experience from co-founding Aragon and Seragon Pharmaceuticals, both of which were also focused on hormone-dependent cancer therapeutics.

Founding Vision

The company's establishment was driven by the founders' recognition of drug resistance as a major challenge in cancer therapy. Their core mission was to develop innovative small molecule therapies to overcome these resistance mechanisms.

Key Founders

Charles L. Sawyers, Scott Lowe, and Richard A. Heyman are the scientific minds behind the company's inception. Richard A. Heyman's prior entrepreneurial success in the oncology space provided a strong foundation.

Early Funding

In October 2016, the company successfully raised $50 million in a Series A financing round. This significant initial funding underscored the confidence in the founding team's strategy.

Lead Investors

Foresite Capital led the Series A funding round, with substantial participation from Taiho Ventures, Boxer Capital, and Alexandria Venture Investments. This early institutional backing was crucial for the company's development.

Strategic Focus

The foundational strategy was shaped by the founders' vision to create novel small molecule therapies. These therapies were specifically designed to target and combat resistance mechanisms in cancer treatment.

Richard A. Heyman's Background

Richard A. Heyman's experience co-founding previous pharmaceutical ventures, such as Aragon and Seragon Pharmaceuticals, provided valuable insights. His expertise in hormone-dependent cancer therapeutics was instrumental in shaping the company's direction.

While specific equity splits at the company's inception are not publicly disclosed, the early investment agreements were directly tied to the founding team's strategic vision. This vision centered on developing innovative small molecule therapies to address the critical issue of drug resistance in cancer treatment. The company's early trajectory and the Marketing Strategy of ORIC Pharmaceuticals were significantly influenced by this foundational scientific and entrepreneurial drive.

Complete ORIC Pharmaceuticals Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

ORIC Pharmaceuticals became a publicly traded entity following its Initial Public Offering (IPO) on April 24, 2020, on The Nasdaq Global Select Market. This event significantly altered its ownership structure, transitioning from private to public hands and allowing a broader base of investors to acquire stakes in the company.

The ownership landscape of ORIC Pharmaceuticals is predominantly shaped by institutional investors, reflecting confidence in the company's development pipeline and strategic direction. As of March 31, 2025, a substantial number of institutional entities held a significant portion of the company's shares, underscoring the interest from professional money managers. This broad institutional backing is crucial for a publicly traded company, as it often signifies stability and a positive outlook on future performance. The company's focus on advancing its clinical candidates, such as ORIC-114 and ORIC-944, coupled with recent financing efforts to extend its operational runway, likely contributes to this investor interest. Understanding who owns ORIC Pharmaceuticals involves recognizing the influence of these large investment firms alongside the holdings of its own leadership.

Key Stakeholders in ORIC Pharmaceuticals

Institutional investors represent a significant portion of ORIC Pharmaceuticals' shareholder base. These entities play a vital role in the company's financial stability and market perception.

• Viking Global Investors Lp is a major institutional shareholder.
• BlackRock, Inc. also holds a substantial number of shares.
• Nextech Invest, Ltd. maintains a notable stake as of recent filings.
• Pfizer Inc. held a significant percentage of outstanding shares as of December 31, 2024.
• Insider ownership, including executives and directors, accounts for 6.82% as of July 30, 2025.

The evolution of ORIC Pharmaceuticals' ownership structure began with its IPO on April 24, 2020, which saw the sale of 7,500,000 shares at $16.00 each, raising $120.0 million. The underwriters' subsequent exercise of their option to purchase an additional 1,125,000 shares further increased the total gross proceeds to $138.0 million. This public offering made ORIC Pharmaceuticals stock available to a wider investment community. As of March 31, 2025, institutional investors were the primary holders, with 329 entities filing relevant disclosures and collectively owning 93,350,795 shares. Among these, Viking Global Investors Lp held 6,572,700 shares, BlackRock, Inc. held 5,435,087 shares, and Nextech Invest, Ltd. held 5,285,714 shares. Other significant institutional investors include Alkeon Capital Management Llc with 4,004,096 shares, Column Group LLC with 3,540,777 shares, EcoR1 Capital, LLC with 3,418,068 shares, Vanguard Group Inc with 3,215,887 shares, and VR Adviser, LLC with 3,182,527 shares. Additionally, Pfizer Inc. held 5.38 million shares as of December 31, 2024, representing 7.57% of the company's outstanding shares. The leadership team and directors, representing insider ownership, held 6.82% of the company's stock as of July 30, 2025. This diverse ownership base highlights the broad interest in ORIC Pharmaceuticals' Growth Strategy of ORIC Pharmaceuticals.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The board of directors for ORIC Pharmaceuticals is comprised of individuals who represent significant shareholder interests and independent expertise. As of August 4, 2024, Richard Heyman holds the position of Chairman and is also a founder and member of the Scientific Advisory Board. Other key members of the board include Mardi C. Dier, Steve L. Hoerter, Lori Kunkel, and Angie You. Jacob Chacko serves as the President, Chief Executive Officer, and a member of the Board, overseeing the company's strategic direction.

The voting power within ORIC Pharmaceuticals adheres to a standard one-share-one-vote structure, typical for publicly traded entities. Shareholders of record can cast their votes through various channels, including the internet, telephone, or by submitting a proxy card, with the annual meeting of stockholders conducted virtually. There is no publicly available information to suggest the existence of dual-class shares, special voting rights, golden shares, or founder shares that would confer disproportionate control to specific individuals or entities beyond their equity holdings. Recent filings, such as the proxy statement dated April 23, 2025, for the June 11, 2025, Annual Meeting of Stockholders, confirm the election of Class II directors, Steven L. Hoerter and Angie You, for three-year terms. The company has not experienced any widely publicized proxy contests or activist campaigns that have significantly influenced its decision-making processes in recent times, reflecting a stable leadership structure.

Understanding ORIC Pharmaceuticals' Governance

The governance structure of ORIC Pharmaceuticals is designed to balance shareholder representation with independent oversight. Key leadership roles and the voting principles are central to understanding ORIC Pharmaceuticals ownership and how decisions are made.

• Board composition reflects both founder representation and independent expertise.
• Voting power is generally aligned with share ownership on a one-share-one-vote basis.
• Shareholders have multiple avenues to participate in voting processes.
• Recent director elections indicate continuity in leadership appointments.
• The company's history shows a consistent approach to corporate governance.

ORIC Pharmaceuticals Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Over the past few years, ORIC Pharmaceuticals has experienced significant shifts in its ownership structure, largely driven by strategic financing initiatives. These developments highlight a growing interest from institutional investors in the company's progress.

Recent financing rounds have bolstered the company's financial standing, with projections indicating extended operational runway. These capital infusions are critical for advancing its clinical pipeline and supporting ongoing research and development efforts.

Recent Financing Rounds

In January 2024, a private placement raised $125 million. A subsequent private placement in May 2025 also generated $125 million.

Extended Operational Runway

The May 2025 funding is expected to support operations into the second half of 2027. This provides a stable outlook for continued development.

Insider and Institutional Activity

While some executives have engaged in insider selling, Director Angie You made a significant purchase in June 2025. Institutional investors hold a substantial majority of the company's stock.

Share Price Performance

As of July 25, 2025, the share price stood at $11.44. This reflects a modest increase from $11.13 recorded on July 29, 2024.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE